261 related articles for article (PubMed ID: 30334334)
1. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
Marcelletti JF; Sikic BI; Cripe LD; Paietta E
Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
[TBL] [Abstract][Full Text] [Related]
2. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).
Tang R; Faussat AM; Perrot JY; Marjanovic Z; Cohen S; Storme T; Morjani H; Legrand O; Marie JP
BMC Cancer; 2008 Feb; 8():51. PubMed ID: 18271955
[TBL] [Abstract][Full Text] [Related]
3. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.
Marcelletti JF; Multani PS; Lancet JE; Baer MR; Sikic BI
Leuk Res; 2009 Jun; 33(6):769-74. PubMed ID: 18976810
[TBL] [Abstract][Full Text] [Related]
4. Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.
Marcelletti JF; Sikic BI
Cancer Chemother Pharmacol; 2024 Jun; 93(6):595-604. PubMed ID: 38407601
[TBL] [Abstract][Full Text] [Related]
5. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
6. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.
Cripe LD; Uno H; Paietta EM; Litzow MR; Ketterling RP; Bennett JM; Rowe JM; Lazarus HM; Luger S; Tallman MS
Blood; 2010 Nov; 116(20):4077-85. PubMed ID: 20716770
[TBL] [Abstract][Full Text] [Related]
7. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
Tang R; Cohen S; Perrot JY; Faussat AM; Zuany-Amorim C; Marjanovic Z; Morjani H; Fava F; Corre E; Legrand O; Marie JP
BMC Cancer; 2009 Jun; 9():199. PubMed ID: 19549303
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.
Marcelletti JF; Sikic BI
Cancer Chemother Pharmacol; 2023 Nov; 92(5):369-380. PubMed ID: 37603048
[TBL] [Abstract][Full Text] [Related]
9. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.
Leith CP; Chen IM; Kopecky KJ; Appelbaum FR; Head DR; Godwin JE; Weick JK; Willman CL
Blood; 1995 Sep; 86(6):2329-42. PubMed ID: 7545025
[TBL] [Abstract][Full Text] [Related]
10. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.
Tan SF; Dunton W; Liu X; Fox TE; Morad SAF; Desai D; Doi K; Conaway MR; Amin S; Claxton DF; Wang HG; Kester M; Cabot MC; Feith DJ; Loughran TP
J Lipid Res; 2019 Jun; 60(6):1078-1086. PubMed ID: 30962310
[TBL] [Abstract][Full Text] [Related]
11. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts.
Pallis M; Turzanski J; Langabeer S; Russell NH
Adv Exp Med Biol; 1999; 457():77-88. PubMed ID: 10500783
[TBL] [Abstract][Full Text] [Related]
12. Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts.
Sonneveld P; Wiemer E
Leukemia; 1997 Jul; 11(7):1160-5. PubMed ID: 9205006
[TBL] [Abstract][Full Text] [Related]
13. The role of drug efflux pumps in acute myeloid leukemia.
van der Kolk DM; de Vries EG; Müller M; Vellenga E
Leuk Lymphoma; 2002 Apr; 43(4):685-701. PubMed ID: 12153153
[TBL] [Abstract][Full Text] [Related]
14. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia.
Pallis M; Turzanski J; Harrison G; Wheatley K; Langabeer S; Burnett AK; Russell NH
Br J Haematol; 1999 Feb; 104(2):307-12. PubMed ID: 10050713
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis.
Xu K; Zhuang XX; Shi XW
Expert Rev Hematol; 2024; 17(1-3):87-94. PubMed ID: 38230679
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
[TBL] [Abstract][Full Text] [Related]
17. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
[TBL] [Abstract][Full Text] [Related]
18. Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
Smeets ME; Raymakers RA; Vierwinden G; Pennings AH; Wessels H; de Witte T
Blood; 1999 Oct; 94(7):2414-23. PubMed ID: 10498614
[TBL] [Abstract][Full Text] [Related]
19. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
20. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
